Review Highlights Latest Advances and Emerging Therapies for Obesity Management

Obesity remains a pervasive global health challenge, significantly increasing the risk of numerous comorbidities such as type 2 diabetes, cardiovascular disease, and certain cancers. While lifestyle interventions are foundational, many individuals require additional support, and existing pharmacological treatments have historically offered limited efficacy. This comprehensive review addresses the critical need for an updated synthesis of current evidence and a forward-looking perspective on novel pharmacological strategies for obesity management.

The review highlighted the transformative impact of incretin-based therapies, particularly GLP-1 receptor agonists (GLP-1 RAs) like semaglutide, which consistently demonstrated average body weight reductions of 15-20% in clinical trials. Dual GIP/GLP-1 receptor agonists, such as tirzepatide, showed even greater efficacy, with some studies reporting over 20% body weight reduction from baseline. Emerging therapies targeting multiple pathways, including amylin analogs and GDF15 mimetics, are showing promising early results, indicating potential for further advancements. These newer agents consistently outperformed older medications, which typically achieved 5-10% weight loss, offering a 2-3 fold improvement in efficacy. The most impactful finding was the paradigm shift towards highly effective pharmacological agents, with over 15% body weight loss now achievable for many patients, significantly improving obesity-related comorbidities and quality of life.